DNA Testing for PCOS in India: What Your Genes Reveal About Hormonal Health

India has one of the world's highest PCOS prevalence rates: 20–25% of Indian women of reproductive age, compared to 6–12% in European women. PCOS — Polycystic Ovary Syndrome — is not a single condition. It is a syndrome with multiple subtypes driven by different underlying mechanisms, and which subtype a woman has determines which treatments are most effective. Genetics explains a significant proportion of both PCOS risk and PCOS subtype — and a DNA test can give Indian women with PCOS or PCOS risk far more targeted information than a generic diagnosis.

What PCOS Actually Is and Why It Looks Different in Indian Women

PCOS is diagnosed using the Rotterdam criteria, which require two of three features: irregular or absent menstrual periods, hyperandrogenism (elevated male hormones in blood tests or clinical signs like acne and hirsutism), and polycystic ovary morphology on ultrasound. Because only two of three criteria are needed, PCOS can manifest as quite different clinical pictures — and the subtype matters enormously for treatment.

Indian women with PCOS more commonly show the insulin-resistant phenotype: metabolic syndrome features, weight dysregulation, insulin resistance, and relatively normal or borderline androgen levels. This contrasts with the hyperandrogenic phenotype more commonly identified in European women, which is dominated by clear androgen excess (acne, hirsutism, alopecia) with less prominent metabolic features.

Why does this matter? Because treatment for insulin-resistant PCOS is different. Insulin sensitisers — particularly metformin — are especially relevant for this phenotype. Targeting insulin resistance through diet, exercise, and medication has outsized impact on menstrual regularity and fertility outcomes in insulin-resistant PCOS compared to primarily hyperandrogenic PCOS. Indian women who receive only anti-androgen treatment without addressing insulin resistance are often undertreated for the dominant mechanism of their PCOS.

Key PCOS-Linked Genes

INSR: Insulin Receptor

The INSR gene encodes the insulin receptor — the protein on cell surfaces that binds insulin and transmits the signal for glucose uptake. Variants in INSR affect receptor sensitivity: lower-sensitivity variants mean cells are less responsive to circulating insulin, requiring the pancreas to produce more insulin to achieve the same glucose-lowering effect. This compensatory hyperinsulinaemia directly drives ovarian androgen production.

For the insulin-resistant PCOS phenotype that predominates in Indian women, INSR variants are directly mechanistically relevant. They help explain why some women develop significant insulin resistance and metabolic PCOS even at healthy body weights — the resistance is partially at the receptor level, not solely driven by adiposity.

FSHR: FSH Receptor

The FSHR gene encodes the follicle-stimulating hormone receptor on ovarian granulosa cells. FSH drives follicular development — the process by which eggs mature in follicles before ovulation. In PCOS, this process is arrested at an early stage, producing the characteristic string-of-pearls appearance of multiple small follicles on ultrasound.

FSHR variants affect how sensitively the ovary responds to FSH stimulation. This matters both for understanding PCOS pathology and — critically — for fertility treatment planning. FSHR genotypes predict ovarian stimulation response: some variants are associated with hyper-response (risk of ovarian hyperstimulation syndrome during IVF), while others predict poor response. A fertility specialist managing PCOS and planning ovulation induction or IVF can use FSHR genotype to calibrate starting doses of gonadotropin stimulation.

LHCGR: LH/HCG Receptor

LH hypersecretion is a defining characteristic of PCOS — particularly in the hyperandrogenic phenotype. Elevated LH drives androgen production in ovarian theca cells, and the ratio of LH to FSH in PCOS is characteristically elevated. The LHCGR gene encodes the receptor for both LH and HCG, and its variants modulate how strongly the ovary responds to LH stimulation. Higher-sensitivity LHCGR variants may contribute to exaggerated androgen responses to LH even at LH levels that would not cause excess androgen production in carriers of lower-sensitivity variants.

AMH: Anti-Müllerian Hormone

AMH is elevated in PCOS — often two to three times the levels seen in women without PCOS — reflecting the large number of antral follicles that characterise the condition. AMH is produced by granulosa cells of growing follicles; more small follicles means more AMH. The AMH gene has variants that affect AMH expression levels, independent of follicle count.

AMH is also used clinically to assess ovarian reserve — the remaining supply of eggs. In PCOS, very high AMH can paradoxically indicate both a large follicle pool (characteristic of PCOS) and challenge interpretation of reserve testing. Understanding AMH gene variants helps contextualise clinical AMH measurements.

CYP11A1: Androgen Synthesis Rate-Limiter

The CYP11A1 gene encodes the cholesterol side-chain cleavage enzyme, which catalyses the rate-limiting first step in steroid hormone synthesis in the ovary and adrenal gland. This enzyme converts cholesterol into pregnenolone — the precursor to all steroid hormones including androgens.

A (TTTTA)n repeat polymorphism in the CYP11A1 promoter region affects gene expression: longer repeats are associated with higher enzyme activity and greater androgen synthesis capacity. Women with high-activity CYP11A1 variants show a stronger propensity toward the hyperandrogenic PCOS phenotype. Understanding this variant helps predict whether hyperandrogenism will be a dominant feature and whether anti-androgen treatments will be particularly warranted.

FTO: Obesity Risk and Insulin Resistance Pathway

The FTO gene — the obesity risk gene discussed in the nutrition context — increases PCOS risk partly through the insulin resistance pathway and partly through appetite dysregulation that affects adipose tissue endocrine signalling. Adipose tissue, particularly visceral fat, secretes hormones (adipokines) that modulate insulin sensitivity and androgen levels. FTO risk variants increase adipose accumulation, which amplifies insulin resistance and androgen excess in PCOS.

For women with PCOS who carry FTO risk variants, structured dietary approaches targeting insulin resistance are particularly important — both because of the direct insulin effect and because of the adiposity-androgen axis. This is one of the clearest examples of how genetic information can help prioritise which lifestyle interventions will have most impact.

Pharmacogenomics for PCOS Medications

One of the most practically useful aspects of genetic testing for PCOS is pharmacogenomics — how your genetic variants affect the way your body processes specific drugs used to treat PCOS.

Metformin: OCT1/OCT2 Transporters

Metformin is one of the most commonly prescribed medications for insulin-resistant PCOS in India. It works by improving insulin sensitivity in the liver and peripheral tissues. But metformin must first enter cells to reach its target enzyme — and it relies on organic cation transporters (OCT1, encoded by SLC22A1, and OCT2, encoded by SLC22A2) to do so.

Variants in SLC22A1 that reduce OCT1 activity result in reduced metformin uptake in liver cells — directly reducing the drug's effectiveness at standard doses. Women with poor-transporter OCT1 variants may require higher metformin doses to achieve equivalent therapeutic effect, or may be poor responders to metformin regardless of dose. This is a clinically meaningful pharmacogenomic finding: if metformin is not working as expected, OCT1 genotype is worth investigating.

Clomiphene: CYP2D6

Clomiphene citrate (clomifene) is the first-line medication for ovulation induction in PCOS fertility treatment. It is metabolised primarily by CYP2D6. The CYP2D6 gene has numerous variants creating a spectrum from ultra-rapid metabolisers (who clear the drug very quickly) to poor metabolisers (who accumulate it).

Poor CYP2D6 metabolisers will have higher clomiphene exposure at standard doses — potentially increasing response (sometimes too strong a response, requiring dose reduction) and side effects. Ultra-rapid metabolisers may clear clomiphene too quickly for therapeutic effect at standard doses. Knowing your CYP2D6 status allows a fertility specialist to start with the most appropriate dose rather than treating every patient identically.

Oral Contraceptives: CYP3A4

Oral contraceptive pills (OCPs) are commonly used to manage PCOS symptoms including irregular periods, acne, and hirsutism. Oestrogen and progesterone components of OCPs are metabolised primarily by CYP3A4. CYP3A4 variants affect drug metabolism speed — poor metabolisers have higher hormone exposure (potentially increasing side effects), while rapid metabolisers may have reduced contraceptive efficacy. This is relevant both for symptom management effectiveness and for women using OCPs who also have cardiovascular risk factors that make higher oestrogen exposure more concerning.

What Origins+ Covers for PCOS

Origins+ includes genetics relevant to PCOS through its health variants and pharmacogenomics panels:

• Insulin resistance genetics — INSR variants relevant to the metabolic PCOS phenotype
• FSHR variants — follicular development and ovarian stimulation response
• FTO — adiposity-insulin resistance pathway relevant to PCOS
• CYP11A1 variants — androgen synthesis and hyperandrogenic phenotype predisposition
• Pharmacogenomics — metformin transporter (OCT1/SLC22A1), CYP2D6 for clomiphene, CYP3A4 for oral contraceptives
• Nutrition traits — fat vs carbohydrate sensitivity, caffeine metabolism, and other wellness markers directly relevant to managing insulin resistance through lifestyle

A note on what is not covered: comprehensive PCOS genetic panels at specialist reproductive genomics centres cover a much broader set of variants, including rare pathogenic variants in genes like DENND1A, THADA, and ERBB4 that have been associated with PCOS through genome-wide association studies. Origins+ provides the most clinically actionable subset of well-established variants. Women with complex, treatment-resistant PCOS or strong family history may benefit from additional specialist genomic testing alongside Origins+.

What DNA Testing Cannot Do for PCOS

It is important to be precise about the limits of genetic testing for PCOS:

• Cannot diagnose PCOS. Diagnosis requires clinical evaluation — menstrual history, blood tests for androgens and hormones, pelvic ultrasound. A DNA test alone cannot diagnose PCOS or rule it out.
• Cannot predict PCOS severity. The same genetic variants can be present in women with mild, easily managed PCOS and in women with severe, treatment-resistant disease. Severity depends on gene-environment interactions that genetics alone cannot predict.
• Cannot replace an endocrinologist or gynaecologist. Genetic results are one layer of information to bring to a specialist. They add context to your clinical picture — they do not replace the clinical assessment.
• Cannot guarantee treatment response. Pharmacogenomic information increases the probability of getting treatment right sooner — it does not guarantee any particular medication will work for you.

The Lifestyle-Genetics Interaction in PCOS

PCOS genetic risk is highly modifiable through lifestyle — more so than many other genetically influenced conditions. This is genuinely good news and worth emphasising. The reason is mechanistic: PCOS in the insulin-resistant phenotype is substantially driven by a modifiable physiological state (insulin resistance). Genetics determines your baseline sensitivity to insulin resistance, but lifestyle significantly determines whether that genetic tendency actually manifests as PCOS symptoms.

Women with FTO risk and INSR variants who achieve and maintain good insulin sensitivity through dietary carbohydrate management, strength training (which dramatically improves skeletal muscle insulin sensitivity), and adequate sleep often see remarkable improvement in PCOS symptoms — menstrual regularity, acne, hair growth patterns — that mirrors or exceeds what medication alone achieves.

Understanding your genetic subtype helps target which lifestyle interventions are most likely to have impact. For FTO carriers, structured eating and resistance exercise are particularly high-yield. For women with CYP11A1 hyperandrogenic variants, anti-androgen dietary approaches (spearmint tea has some evidence; soy isoflavones have evidence in some populations) may add value alongside conventional treatment.

The Fertility Angle

PCOS is the leading cause of anovulatory infertility in India — irregular or absent ovulation means eggs are not consistently released, making conception unreliable. Understanding your genetic profile can inform conversations with a fertility specialist in several ways:

FSHR genotype predicts ovarian stimulation response — useful for IVF protocol planning. CYP2D6 genotype predicts clomiphene metabolism — relevant for starting dose in ovulation induction. Insulin resistance genetics inform whether metformin co-treatment alongside ovulation induction drugs is likely to be beneficial for your specific profile. AMH gene variants help contextualise your AMH level reading — elevated AMH in PCOS does not necessarily mean the same thing for all PCOS patients, and genetic context adds nuance.

Arriving at a fertility consultation with Origins+ pharmacogenomic data is increasingly something reproductive specialists in India find useful — it reduces the trial-and-error component of ovulation induction dosing and gives a clearer picture of likely treatment trajectory.

Frequently Asked Questions

Can a DNA test diagnose PCOS?

No. PCOS is a clinical diagnosis based on the Rotterdam criteria: two of three features — irregular periods, biochemical or clinical signs of hyperandrogenism, and polycystic ovaries on ultrasound. This requires a gynaecologist or endocrinologist evaluation, blood tests, and often a pelvic ultrasound. A DNA test can tell you whether you carry genetic variants associated with elevated PCOS risk and which subtype you may be predisposed to — it cannot tell you whether you currently have PCOS.

Why do Indian women have higher PCOS rates than European women?

Several converging factors explain the higher prevalence. South Asian populations have higher baseline rates of insulin resistance than European populations — independent of weight. This insulin resistance predisposes to the metabolic PCOS phenotype. INSR and FTO variants relevant to insulin sensitivity are present at higher frequencies in South Asian gene pools. Dietary patterns high in refined carbohydrates, compounded by insulin resistance genetics, create a larger pool of women in whom insulin-driven androgen excess develops. Additionally, the insulin-resistant PCOS phenotype that dominates in Indian women may go undiagnosed longer because classic androgenic signs are less prominent.

If PCOS runs in my family, will my daughter definitely get it?

No. PCOS is a polygenic condition with high heritability (roughly 70% of variance is genetic), but having PCOS risk genes does not guarantee the condition will manifest. PCOS genetic risk is substantially modifiable through lifestyle — particularly maintaining insulin sensitivity through diet and exercise. If PCOS runs in your family, a genetic test can clarify which variants are present, and that information can guide preventive lifestyle choices from adolescence onward.

How does pharmacogenomics help women managing PCOS with medication?

Pharmacogenomics reveals how your genetic variants affect drug processing. For PCOS, this matters for metformin (OCT1/OCT2 transporter variants affect uptake and efficacy), clomiphene ovulation induction (CYP2D6 variants affect drug levels — poor metabolisers may need lower doses), and oral contraceptives (CYP3A4 variants affect oestrogen and progesterone metabolism). Knowing your pharmacogenomic profile helps your specialist choose the most appropriate treatment and dose from the outset, reducing the trial-and-error phase of PCOS management.

I have PCOS and insulin resistance — which Helixline kit is most relevant?

Origins+ is the most relevant kit. It includes insulin resistance genetics (INSR, FTO), relevant hormonal metabolism variants, pharmacogenomics covering metformin transport, CYP2D6 for clomiphene, and CYP3A4 for oral contraceptives, as well as nutrition and wellness traits directly applicable to managing insulin resistance through diet. For most women with PCOS seeking genetic insight relevant to their current management, Origins+ at ₹12,999 provides the most immediately actionable information.